An update on the prevention of influenza in children and adolescents

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Influenza virus types A and B are responsible for annual respiratory tract infection outbreaks affecting all age groups, including children and adolescents.
• Complications such as high fever, febrile convulsions, secondary bacterial infections, and myositis frequently result in hospitalization.
• Safe and effective influenza vaccines (split, subunit, and virosome) are available for individuals aged 6 months and older.

Purpose of the Study:

• To review the current strategies for influenza vaccination in European countries.
• To highlight the challenges and barriers to achieving adequate immunization compliance.
• To discuss the role of neuraminidase inhibitors as a secondary option for influenza prophylaxis.

Main Methods:

• Review of existing European guidelines for influenza vaccine use.
• Analysis of factors contributing to poor physician and patient compliance with immunization recommendations.
• Discussion of the therapeutic and prophylactic applications of neuraminidase inhibitors.

Main Results:

• Current influenza vaccination strategies in Europe primarily focus on high-risk groups, with definitions varying across countries.
• Identified barriers to immunization significantly impact compliance rates among both healthcare providers and patients.
• Neuraminidase inhibitors offer curative and preventive efficacy against influenza A and B, serving as a second-line option.

Conclusions:

• Addressing identified barriers to influenza immunization is crucial for improving public health outcomes.
• Enhanced compliance with vaccination recommendations is needed to reduce the burden of influenza disease.
• Neuraminidase inhibitors provide an important alternative for influenza prevention and treatment in specific circumstances.